Vitamin C May Help Blood Cancer Patients Live Longer

A common vitamin found in any pharmacy might help people with precancerous blood conditions live longer, according to promising new research that could transform how doctors protect patients at risk of leukemia.

The EVITA clinical trial studied 109 people with conditions that can progress to acute myeloid leukemia, an aggressive blood cancer that's notoriously difficult to treat. Half took 1,000 mg of vitamin C daily for a year while the other half received a placebo pill. Neither patients nor doctors knew who was getting what.

The results surprised even the researchers. After three years of follow-up, participants who received vitamin C were significantly more likely to still be alive than those who took the placebo. They also experienced fewer adverse health events during the study period.

"We are tremendously excited and cautiously optimistic that our results could one day translate into a simple way to improve care and outcomes for people with pre-leukemia disorders," said Dr. Peter A. Jones, a distinguished professor at Van Andel Institute who co-led the research.

The vitamin didn't slow the growth of abnormal blood cells directly. Instead, it appeared to change levels of immune signaling molecules called cytokines in ways that researchers link to better outcomes. Scientists believe vitamin C might help restore normal function in blood cells that are at risk of becoming cancerous.

This matters because millions of older adults develop these precancerous blood conditions, and right now there's no approved treatment to stop them from becoming leukemia. Many patients can't undergo stem cell transplants because of age or other health issues, leaving them with few options.

Why This Inspires

What makes this discovery particularly exciting is its accessibility. The researchers used an oral dose comparable to over-the-counter vitamin C supplements, not expensive infusions or complicated treatments. If confirmed in larger trials, this intervention could be available to anyone at risk, regardless of income or location.

The study was the first randomized, double-blind, placebo-controlled trial to test daily oral vitamin C in patients with conditions that precede leukemia. This gold-standard approach makes the findings more reliable than previous research, which had mostly looked at intravenous vitamin C for solid tumors rather than blood cancers.

Dr. Kirsten Grønbæk, the lead researcher and a hematologist at the University of Copenhagen, emphasized that it's too early to make definitive recommendations. The team needs to verify these results in a larger phase 3 trial before doctors can confidently prescribe vitamin C for this purpose.

Still, the research represents a growing shift toward cancer interception, catching and stopping disease before it fully develops rather than fighting it after diagnosis. For people living with the uncertainty of precancerous conditions, that's a future worth hoping for.